Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-09-05
2006-09-05
Ungar, Susan (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S357000, C530S387700, C530S388100, C530S388500, C530S358000, C530S389100, C530S388700
Reexamination Certificate
active
07101976
ABSTRACT:
The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.
REFERENCES:
patent: 5824303 (1998-10-01), Bartley et al.
patent: 2001/0031252 (2001-10-01), Low et al.
patent: WO 93/00425 (1993-01-01), None
patent: WO 94/29348 (1994-12-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 00/30673 (2000-06-01), None
patent: WO 01/12840 (2001-02-01), None
Asaheim et al. “A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes.”Blood. 2000;95(1):221-30.
Andres et al., “Expression of two noveleph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis,”Oncogene, 1994; 9:1463-1467.
Baggliolini et al. “Interleukin-8 and the Chemokine Family”Int. J. Immunopharmae 1995;17(2):103-108.
Biervert et al. “Semiquantitative expression analysis of ephrine-receptor tyrosine kinase mRNA's in a rat model of traumatic brain injury.”Neurosci Lett. 2001;315(1-2):25-8.
Blanco et al. “Expression of EphA receptors and ligands during chick cerebellar development.”Mech Dev. 2002;114(1-2):225-9.
Bodansky et al., Ed.,Principles of Peptide Synthesis, Springer-Verlag Inc., NY, 1993, Cover pg., Publication pg., and Table of Contents.
Boerner et al.“Production of antigen-Specific Human Monoclonal Antibodies from in vitro-primed Human Splenocytes”,J. Immunol., 1991; 147(1):86-95.
Bohme et al. “PCR mediated detection of a new human receptor-tyrosine-kinase, HEK 2.”Oncogene. 1993;8(10):2857-62.
Bovenkamp et al. “egenerate PCR-based cloning method for Eph receptors and analysis of their expression in the developing murine central nervous system and vasculature”DNA Cell Biol. 2001:20(4):203-13.
Brady-Kalnay et al., “Dynamic Interaction of PTPμ with Multiple Cadherins In Vivo”J. Cell Biol., 1998; 141:287-296.
Brantley et al. “Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.”Oncogene. 2002;21(46):7011-26.
Bruggemann et al., “Designer mice: the production of human antibody repertoires in transgenic animals”Year Immunol. 1993;7:33-40.
Burgess et al. “Possible Dissociation of the Heparin-binding Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutgensis of a Single Lysine Residue”J. Cell Biology1990;111:2129-2138.
Carles-Kinch “Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior,”Cancer Research2002;62:2840-2847.
Carter et al. “EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas).”Nat Cell Biol. 2002;4(8):565-73.
Chen et al. “An enhancer element in the EphA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXA1 and HOXB1 homeobox proteins.”J Biol Chem. 1998;273(38):24670-5.
Chen et al. “Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap tetroviral insertion.”Oncogene1996;12(5):979-88.
Chen et al., “Integrin-mediated cell adhesion activates mitogen-activated protein kinases,”J. Biol. Chem., 1994;269:26002-26005.
Cheng et al. “Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis.”Mol Cancer Res. 2002;1(1):2-11.
Clark et al. “Aberrant function of the Ras signal transduction pathway in human breast cancer”Breast Cancer Res. Treat.1995;35(1):133-144.
Clark et al. “The Ras-related protein Fheb is farnesylated and antagonizes Ras signaling and transformation,”J. Biol. Chem., 1997; 272:10608-10615.
Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, 1985, p. 77.
Connor et al. “Expression and tyrosine phosphorylation of Eph receptors suggest multiple mechanisms in patterning of the visual system.”Dev Biol. 1998;193(1):21-35.
Curti “Physical barriers to drug delivery in tumors” Critical Reviews in Oncology/Hematology1993;14:29-39.
D'Amico “Predicting the Sites of Metastasis Form Lung Cancer Using Molecular Biologic Markets”Ann. Thoracic. Surg. 2001;72:1144-8.
Dawson et al., “Synthesis of Proteins by Native Chemical Ligation,”Science, 1994;266:776-779.
Dermer “Another Anniversary for the War on Cancer” Bio/Technology 1994;12:320.
deLisle et al.,Techniques in Protein Chemistry IV, Academic Press, New York, 1992, pp. 257-267.
DeVita, Jr., “Principles of Cancer Management: Chemotherapy”,Cancer: Principles and Practice of Oncology, Fifth Edition, V. T. Devita Jr. et al., Eds., Lippincott-Raven, Philadelphia, 1997;333-347.
Dohn et al. “Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis.”Oncogene. 2001;20(45):6503-15.
Easty et al., “Novel and Known Protein Tyrosine Kinases and Their Abnormal Expression in Human Melanoma,”J. of Investigative Dermatolog, 1993;101:679-684.
Eatsy et al., “Protein tyrosine kinases in malignant melanoma,”Melanoma Research, 2000;10:401-411.
Easty et al. “Up-regulation of ephrin-A1 during melanoma progression.”Int J Cancer. 1999;84(5):494-501.
Fenrick “TEL, a Putative Tumor Suppressor, Modulates Cell Growth and Cell Morphology of Ras-Transformed Cells While Repressing the Transcription ofstromelysin-1” Molecular and Cellular Biology 2000;20(6):5826-5839.
Ferrone et al., eds.,Handbook of Monoclonal Antibodies, Noges Publications, Park Ridge, N.J., 1985. Chapter 22 and 303-357.
Fidler, “Molecular Biology of Cancer: Invasion and Metastasis”,In Cancer: Principles and Practice of Oncology, V. T. Devita et al, eds. (Philadelphia: Lippincott-Raven), p. 135-152 (1997).
FreshneyCulture of Animal Cells. A Manual of Basic Technique 1983;3-4.
Frisch, “Integrins and anoikis”,Current Opinion in Cell Biology, 1997;9:701-706.
Ganju et al. “The Eck receptor tyrosine kinase is implicated in pattern formation during gastrulation, hindbrain segmentation and limb development.”Oncogene. 1994;9(6):1613-24.
Grant,Synthetic Peptides: A User Guide, W.H. Freeman and Co., N.Y., 1992, Cover pg., Publication pg., and Table of Contents only.
Goding,Monoclonal Antibodies: Priciples and Practice, Academic Press, 1986, pp. 59-103.
Harlow et al.,Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, 1988. Table of Contents Only.
Hartwell et al. “Integrating Genetic Appraoches into the Discovery of Anticancer Drugs”Science1997;278:1064-1068.
Hein, “Regulation of Cell Signaling Induced by the Cell Adhesion Molecule, E-Cadherin,” Ph.D. Thesis, Purdue University, 94 pgs., Cover Date Aug. 1999.
Helbling et al. “Requirement for EphA receptor signaling in the segregation of Xenopus third and fourth arch neural crest cells.”Mech Dev. 1998;78(1-2):63-79.
Henson, “Molecular and genetic targets in early detection”,Current Opinion in Oncology,1999;11:419-425.
Hess et al., “Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (ECK/EphA
Carles-Kinch Kelly
Kilpatrick Katherine E
Kinch Michael Scott
Needle & Rosenberg P.C.
Purdue Research Foundation
SmithKline Beecham Corporation
Ungar Susan
LandOfFree
EphA2 monoclonal antibodies and methods of making and using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EphA2 monoclonal antibodies and methods of making and using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EphA2 monoclonal antibodies and methods of making and using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532997